Immatics Announces First Patient Treated with ACTengine® IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo® (nivolumab) in Patients with Advanced Solid Tumors
May 18, 2022 07:00 ET | https://immatics.com/
The Phase 1b dose expansion cohort will evaluate safety, biological activity and initial anti-tumor activity of IMA203 TCR-T targeting PRAME in combination with nivolumab1, a PD-1 immune checkpoint...
Immatics behandelt ersten Patienten mit ACTengine® TCR-T-Zelltherapie IMA203 in Kombination mit Checkpoint-Inhibitor Opdivo® (Nivolumab) in Patienten mit fortgeschrittenen soliden Tumoren
May 18, 2022 07:00 ET | Immatics N.V.
Die Phase-1b-Dosis-Expansionskohorte untersucht die Sicherheit, biologische Aktivität und erste Anzeichen einer Anti-Tumor-Aktivität der IMA203 TCR-T-Zelltherapie gegen die Zielstruktur PRAME in...
Celyad-Logo-Color.jpg
Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference
May 17, 2022 16:05 ET | Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, May 17, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and...
Gracell_Logo-new.png
Gracell Biotechnologies Reports First Quarter 2022 Unaudited Financial Results and Provides Corporate Update
May 16, 2022 07:30 ET | Gracell Biotechnologies Inc.
Presented early clinical data from a first-in-human Phase 1 investigator-initiated trial (IIT) of allogeneic TruUCAR candidate GC502 for relapsed/refractory B-cell acute lymphoblastic leukemia (r/r...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports First Quarter 2022 Financial Results and Provides Operational Update
May 12, 2022 16:05 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial...
Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors
May 10, 2022 07:00 ET | https://immatics.com/
Patient enrollment for IMA401 Phase 1 trial started at first clinical site in GermanyThe study will evaluate safety, tolerability, and initial anti-tumor activity of IMA401 in patients with recurrent...
Immatics beginnt klinische Phase-1-Studie zur Untersuchung des bispezifischen TCR-Kandidaten IMA401 bei Patienten mit fortgeschrittenen soliden Tumoren
May 10, 2022 07:00 ET | Immatics N.V.
Patientenrekrutierung für die Phase-1-Studie mit IMA401 hat an erstem klinischen Studienzentrum in Deutschland begonnenDie Studie untersucht die Sicherheit, Verträglichkeit und erste...
Bone Therapeutics to host Annual General Meeting and Extraordinary General Meeting on 8 June 2022
May 09, 2022 01:00 ET | Bone Therapeutics SA
REGULATED INFORMATION Preliminary documents for the Annual and Extraordinary General Meeting have been made available on company’s website Mont-Saint-Guibert, Belgium, 9 May 2022, 7am...
Bone Therapeutics tiendra son Assemblée Générale Ordinaire et Assemblée Générale Extraordinaire le 8 juin 2022
May 09, 2022 01:00 ET | Bone Therapeutics SA
INFORMATION REGLEMENTEE Mise à disposition des documents préparatoires à l’assemblée générale ordinaire sur le site internet de la Société Mont-Saint-Guibert, Belgique, le 9 mai 2022 à...
Celyad-Logo-Color.jpg
CORRECTION - Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights
May 05, 2022 18:12 ET | Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, May 05, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Celyad Oncology SA (Euronext & Nasdaq: CYAD), please note that in the...